文章核心观点 公司在2025财年第三季度实现稳健有机增长，符合全年目标，业务势头持续，商业和营收表现强劲，持续执行并购战略，确认2025和2026财年财务目标 [1][5][6]。 各部分总结 业务表现 - 2025财年第三季度总业务量（BVI）达57亿欧元，前九个月达188亿欧元，高于2024财年同期的183亿欧元 [5] - 员工福利业务量在第三季度达46亿欧元，有机增长6.7%，前九个月达142亿欧元，排除一次性影响后有机增长9.0% [7] - 其他产品与服务业务量第三季度达12亿欧元，前九个月达47亿欧元 [8] 营收情况 - 2025财年第三季度总营收3.1亿欧元，有机增长11.1%，报告增长4.3%，受运营收入积极趋势和浮动收入稳定增长推动 [9] - 运营收入2.7亿欧元，有机增长11.1%，报告增长5.4%，受员工福利业务基数效应缓解支撑 [10] - 浮动收入3900万欧元，有机增长10.8%，报告增长 -2.2%，受浮动基数增长和投资收益率提高支撑 [11] - 员工福利运营收入2.34亿欧元，有机增长12.8%，报告增长6.5%，得益于业务量动态和客户接受率提升 [13] - 其他产品与服务运营收入3600万欧元，有机增长0.5%，智利公共福利合同贡献被英美业务调整抵消 [14] - 欧洲大陆运营收入1.2亿欧元，有机增长8.8%，报告增长11.5%，基数效应缓解但宏观经济趋势仍有压力 [16] - 拉丁美洲运营收入1.06亿欧元，有机增长13.6%，报告增长3.4%，受巴西商业执行和智利合同恢复推动，墨西哥受美国政策影响 [17] - 其他地区运营收入4500万欧元，有机增长11.0%，土耳其和印度推动增长，抵消英美业务调整逆风 [18] 并购战略 - 签署收购罗马尼亚MyBenefits公司协议，该公司技术创新，交易将扩展技术能力和加强欧洲大陆市场地位 [20][21] - 收购预计产生协同效应和交叉销售机会，获监管批准后将用现有资金融资，预计2026财年增加经常性EBITDA利润率 [22] - 推进西班牙Cobee和巴西Benefício Fácil整合，与桑坦德银行战略伙伴关系全面运营，支持巴西市场商业拓展 [23] 财务目标 - 确认2025财年财务目标，预计浮动收入有机增长为低两位数 [24] - 2025和2026财年财务目标考虑与桑坦德银行合作和并购交易协同效应 [25] 会议安排 - 公司将于2025年7月3日上午8:30（CET）举行英文投资者和分析师电话会议 [26] 财务日历 - 2025财年年报预计10月30日公布，年度股东大会预计12月17日举行，日期可能变动 [29]

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Protalix BioTherapeutics (PLX) FY 2025 Conference May 20, 2025 04:30 PM ET Speaker0 Is traded publicly under the ticker symbol PLX. My name is Ram Selvaraju, and I'm a Managing Director and Senior Healthcare Equity Research Analyst in Wainwright's Equity Research Division. We cover Protalix with a buy rating and twelve month price target of $10 per share. Presenting for the company will be Chief Financial Officer and Treasurer, Eyal Rubin. Eyal, it's a pleasure to have you with us. Thank you. Speaker1 Thank ...

Protalix BioTherapeutics (PLX) Q1 2025 Earnings Call May 09, 2025 08:30 AM ET Company Participants Mike Moyer - Managing DirectorDror Bashan - President, CEO & DirectorEyal Rubin - SVP and CFODaniel Smith - Equity Research Associate Conference Call Participants John Vandermosten - Senior AnalystDan Akschuti - Equity Partner - Biotech AnalystNone - Analyst Operator Good morning, ladies and gentlemen, and welcome to the Protalix Biotherapeutics First Quarter twenty twenty five Financial and Business Results C ...

Protalix BioTherapeutics (PLX) Q1 2025 Earnings Call May 09, 2025 08:30 AM ET Company Participants Mike Moyer - Managing DirectorDror Bashan - President, CEO & DirectorEyal Rubin - SVP and CFODaniel Smith - Equity Research Associate Conference Call Participants John Vandermosten - Senior AnalystDan Akschuti - Equity Partner - Biotech AnalystNone - Analyst Operator Good morning, ladies and gentlemen, and welcome to the Protalix Biotherapeutics First Quarter twenty twenty five Financial and Business Results C ...

Protalix BioTherapeutics (PLX) Q1 2025 Earnings Call May 09, 2025 08:30 AM ET Speaker0 Good morning, ladies and gentlemen, and welcome to the Protalix Biotherapeutics First Quarter twenty twenty five Financial and Business Results Conference Call. As a reminder, this conference is being recorded. I will now turn the conference over to our host, Mike Moyer of LifeSci Advisors, Investor Relations for Potalix. Thank you. Please go ahead. Speaker1 Thank you, operator, and welcome to the Potalix Biotherapeutics ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR 001-33357 (Commission file number) PROTALIX BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Delaware __65-0643773__ (State or other jurisdiction of incorporatio ...

Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, May 9, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended M ...

Company to host conference call and webcast today at 8:30 a.m. EDTCARMIEL, Israel, May 9, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended March 31, 2025, and provided a business and clinical update."We had another solid qua ...